-
Mashup Score: 4
The FDA has granted priority review to ziftomenib for relapsed/refractory acute myeloid leukemia harboring an NPM1 mutation.
Source: www.onclive.comCategories: General Medicine NewsTweet
-
Mashup Score: 6Revumenib in Triplet Regimen Under Study in Newly Diagnosed AML With NPM1/KMT2A Alterations - 8 day(s) ago
A new combination of azacitidine, venetoclax, and revumenib demonstrated high rates of complete response and clinical activity in older adults with newly diagnosed acute myeloid leukemia and an NPM1 m…
Source: ascopost.comCategories: General Medicine NewsTweet-
Leading the ongoing trial in older adults with NPM1-mutant or KMT2A-rearranged AML, @LeukDocJZ reports the addition of oral revumenib to azacitidine + venetoclax is safe and drives high remission rates, paving the way for a pivotal phase III. #AML https://t.co/wL8Ue3JPbt https://t.co/8CFDJugzNV
-
-
Mashup Score: 3
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet-
Natural killer cells harvested from healthy donors, employing a novel mass-produced therapy, more than doubled the rate for progression-free survival among patients with #AML. https://t.co/1G1YCiuaLY https://t.co/153uIYfrpe
-
-
Mashup Score: 0
Treatment with CPX-351 for patients with newly diagnosed secondary acute myeloid leukemia demonstrates real-world efficacy and safety, according to results from a retrospective study.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
Treatment with CPX-351 for patients with newly diagnosed secondary #AML demonstrates real-world efficacy and safety, according to results from a retrospective study. Learn more: https://t.co/iEX03GrLTS https://t.co/tBxExr3XwY
-
-
Mashup Score: 13Acute Myeloid Leukemia - 15 day(s) ago
Developing quality improvement programs aimed at reducing health care disparities and improving the standard of care received by patients with hematologic cancers are key priorities in ACCC’s educational portfolio.
Source: www.accc-cancer.orgCategories: General Medicine NewsTweet-
I'm delighted to partner with @ACCCBuzz on the development of educational content about acute myeloid leukemia (#AML). Take a look at our recent on-demand webinar, where we dive deeply into the how, what and why of bone marrow aspiration and biopsy: https://t.co/P5IR7vc4Dx
-
-
Mashup Score: 0
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet-
Natural killer cells harvested from healthy donors, employing a novel mass-produced therapy, more than doubled the rate for progression-free survival among patients with #AML. https://t.co/1G1YCiuaLY https://t.co/153uIYfrpe
-
-
Mashup Score: 9
Eunice Wang, MD, provides an overview of currently available AML treatments and highlights the importance of mutational sequencing strategies.
Source: www.onclive.comCategories: General Medicine NewsTweet-
In an interview with OncLive, Dr Eunice Wang of @RoswellPark highlighted: 🩸 Current #AML management updates. 🩸 The importance of performing mutational sequencing across AML subtypes 🩸 Future directions for targeted precision medicine in AML. Read more: https://t.co/eegBBK1ULA https://t.co/wIxf7a2Epm
-
-
Mashup Score: 1
Results from the phase 1b study suggest venetoclax plus modified chemotherapy is an effective and well-tolerated approach.
Source: www.bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
➕ Venetoclax plus a modified intensive chemotherapy regimen offers an effective, well-tolerated, time-limited approach for managing #AML in in older, fit patients. 💡 Learn more about the phase 1b CAVEAT study published in @BloodAdvances. ➡️ https://t.co/m9JS67u5Yk https://t.co/uYMlDN6TF5
-
-
Mashup Score: 1Tuspetinib Triplet Combination Shows Antileukemic Activity in AML | Blood Cancers Today - 1 month(s) ago
Tuspetinib in combination with venetoclax and azacitidine showed promising clinical safety and antileukemic activity in patients with newly diagnosed acute myeloid leukemia.
Source: www.bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
✅ Tuspetinib in combination with standard-of-care venetoclax and azacitidine showed promising clinical safety and antileukemic activity in patients with newly diagnosed #AML. 📖 Read more: https://t.co/ALHXVG8sLK https://t.co/jYZWk7bHKT
-
-
Mashup Score: 5Bridging the Gap: Addressing Disparities in AML Diagnosis, Treatment, and Outcomes | Blood Cancers Today - 2 month(s) ago
An interview with Kelly Chien, MD, conversation explores geographic and institutional differences in the standard of care, the consequences of unequal access and more.
Source: www.bloodcancerstoday.comCategories: General Medicine NewsTweet-
At the second annual HemOnc Pulse Live, Kelly Chien, MD, of @MDAndersonNews, discusses how disparities in access to care, resources, and molecular testing impact outcomes for patients with #AML across diverse populations. 📺 https://t.co/nwJVshMnuz https://t.co/PG09S5GcQi
-
The @US_FDA granted priority review to the NDA seeking full approval of ziftomenib for patients with R/R NPM1-mutant #AML, which was supported by data from the phase 1/2 KOMET-001 trial. Read. more here: https://t.co/WAiwFmVQ1k https://t.co/7654n56YTD